These mHTT-LC3 linker compounds can reduce the level of mHTT in HD cells at nanomolar concentrations and in HD mouse models at a dose of 0.5 mg/kg by intraperitoneal injection. The gene discussed is MAP1LC3A; the disease is Huntington disease.